In AML, OGG1 is not only associated with adverse cytogenetics, and contributes to cytarabine resistance, but it has a particularly adverse effect on disease outcomes in the context of FLT3ITD [122,123]. The gene discussed is OGG1; the disease is acute myeloid leukemia.